# Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients

> **NCT00350792** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 62 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT00350792
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-11
- **Final completion:** 2009-11
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2010-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00350792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00350792, "Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00350792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*